• 1
    Itoh Z. Motilin and clinical application. Peptides 1997; 18: 593608.
  • 2
    Vantrappen G, Janssens J, Peeters TL, Bloom SR, Christofides ND, Hellemans J. Motilin and the interdigestive migrating motor complex in man. Dig Dis Sci 1979; 24: 497500.
  • 3
    Christofides ND, Modlin IM, Fitzpatrick ML, Bloom SR. Effect of motilin on the rate of gastric emptying and gut hormone release during breakfast. Gastroenterology 1979; 76: 9037.
  • 4
    Schmid R, Schusdziarra V, Allescher HD, Bofilias I, Buttermann G, Classen M. Effect of motilin on gastric emptying in patients with diabetic gastroparesis. Diabetes Care 1991; 14: 658.
  • 5
    Itoh Z, Nakaya M, Suzuki T, Arai H, Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am J Physiol 1984; 247: G68894.
  • 6
    Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G. Erythromycin is a motilin receptor agonist. Am J Physiol 1989; 257: G4704.
  • 7
    Annese V, Lombardi G, Frusciante V, Germani U, Andriulli A, Bassotti G. Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus. Aliment Pharmacol Ther 1997; 11: 599603.
  • 8
    Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990; 322: 102831.
  • 9
    Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351: 108996.
  • 10
    Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 2006; 18: 26383.
  • 11
    Talley NJ, Verlinden M, Geenen DJ, et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001; 49: 395401.
  • 12
    Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000; 14: 165361.
  • 13
    Camilleri M. Motilin agonists and dyspepsia: throwing out the baby with the bath water. Gut 2002; 51: 612 (author reply 612–3).
  • 14
    Peeters TL. GM-611 (Chugai Pharmaceutical). Curr Opin Investig Drugs 2001; 2: 5557.
  • 15
    Koga H, Sato T, et al. Potent, acid-stable and orally active macrolide-type motilin receptor agonists, GM-611 and the derivatives. Bioorg Med Chem Lett 1994; 4: 134752.
  • 16
    Ozaki KI, Yogo K, Sudo H, et al. Effects of mitemcinal (GM-611), an acid-resistant nonpeptide motilin receptor agonist, on the gastrointestinal contractile activity in conscious dogs. Pharmacology 2007; 79: 22335.
  • 17
    McCallum RW, Cynshi O. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther 2007; 26: 10716.
  • 18
    Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000; 95: 145662.
    Direct Link:
  • 19
    Buckley MJ, Scanlon C, McGurgan P, O’Morain CA. A validated dyspepsia symptom score. Ital J Gastroenterol Hepatol 1997; 29: 495500.
  • 20
    Tack J, Janssens J, Vantrappen G, et al. Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterology 1992; 103: 729.
  • 21
    Verhagen MA, Samsom M, Maes B, Geypens BJ, Ghoos YF, Smout AJ. Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther 1997; 11: 107786.
  • 22
    Ghoos YF, Maes BD, Geypens BJ, et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993; 104: 16407.
  • 23
    Tack J, Peeters T. What comes after macrolides and other motilin stimulants? Gut 2001; 49: 3178.
  • 24
    Thielemans L, Depoortere I, Perret J, et al. Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther 2005; 313: 1397405.
  • 25
    Ueno N, Inui A, Asakawa A, et al. Erythromycin improves glycaemic control in patients with Type II diabetes mellitus. Diabetologia 2000; 43: 4115.
  • 26
    Nakamura T, Ishii M, Arai Y, Tandoh Y, Terada A, Takebe K. Effect of intravenous administration of EM523 L on gastric emptying and plasma glucose levels after a meal in patients with diabetic gastroparesis: a pilot study. Clin Ther 1994; 16: 98999.
  • 27
    Horowitz M, Maddox A, Bochner M, et al. Relationships between gastric emptying of solid and caloric liquid meals and alcohol absorption. Am J Physiol 1989; 257: G2918.
  • 28
    Horowitz M, O’Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 2002; 19: 17794.